Search company, investor...


Founded Year




Total Raised


Date of IPO


About Sirnaomics

Sirnaomics (02257.HK) develops a portfolio of intellectual properties in therapeutic areas of interest including anti-fibrotic medicine, cancer therapeutics, and others. STP705 is an anti-fibrosis siRNA (small interfering RNA) therapeutic candidate, which leverages a dual-targeted inhibitory property and PNP-enhanced delivery to directly diminish the tissue fibrotic activity in various animal models, from skin hypertrophic scar to liver and lung fibrosis.

Headquarters Location

401 Professional Drive Suite 280

Gaithersburg, Maryland, 20859,

United States


Missing: Sirnaomics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Sirnaomics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Sirnaomics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Sirnaomics is included in 4 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



1,899 items

Sirnaomics Patents

Sirnaomics has filed 1 patent.

The 3 most popular patent topics include:

  • Transcription factors
  • Clusters of differentiation
  • Experimental cancer drugs
patents chart

Application Date

Grant Date


Related Topics




Molecular biology, Clusters of differentiation, Transcription factors, Virus families, Animal virology


Application Date


Grant Date



Related Topics

Molecular biology, Clusters of differentiation, Transcription factors, Virus families, Animal virology



Latest Sirnaomics News

Global Respiratory Monitoring Devices Market Key Opportunities And Strategies For 2022-2026

Dec 2, 2022

News Provided By Share This Article Respiratory Monitoring Devices Market Report 2022 - Market Size, Trends, And Forecast To 2026 The Business Research Company’s Respiratory Monitoring Devices Global Market Report 2022 : Market Size, Trends, And Forecast To 2026 Avail a limited period discount of 33% on our uniquely designed Opportunities and Strategies market research reports. Contact us today and make winning strategies!” — The Business Research Company LONDON, GREATER LONDON, UK, December 2, 2022 / / -- Avail a limited period discount of 33% on our uniquely designed Opportunities and Strategies market research reports. Contact us today and make winning strategies! The Business Research Company's "Respiratory Monitoring Devices Market Report 2022” forecasts the respiratory monitoring devices market share to reach a value of $1.32 billion in 2022 at a compound annual growth rate (CAGR) of 12.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, effecting many markets across the globe. The respiratory monitoring devices market is expected to grow to $1.84 billion in 2026 at a CAGR of 8.8%. The market for respiratory monitoring devices is experiencing exponential growth due to the COVID-19 pandemic. Request a Sample now to gain a better understanding of respiratory monitoring devices market: The companies in the market are increasingly launching smart respiratory monitoring devices to diagnose and monitor some respiratory diseases. These smart respiratory monitoring devices are Bluetooth-enabled and can be connected to smartphones to continuously monitor vital respiratory parameters. For instance, in November 2019, Lupin Limited, an India-based pharmaceutical company, introduced Adhero, a new connected smart device for metered-dose medications. This first-of-its-kind technology is intended to help people with chronic respiratory illnesses monitor their use of MDI and to promote enhanced therapy adherence. Respiratory Monitoring Devices Market Overview The respiratory monitoring devices market consists of sales of respiratory monitoring devices used to monitor respiration-related parameters that aid the detection of acute or chronic respiratory disorders. The main types of respiratory monitoring devices are capnographs, gas analyzers, pulse oximeters, peak flow meters, spirometers, polysomnography, and others. Capnographs are monitoring devices that measure the concentration of carbon dioxide in exhaled air and display a numerical readout and waveform tracing. The various applications involved are chronic obstructive pulmonary disease (COPD), infectious diseases, asthma, and others that are used by end-users such as laboratories, hospitals, and home use. Learn more on the global respiratory monitoring devices market report at: Market Segmentation By End-User: Laboratories, Hospitals, Home Use By Application: Chronic Obstructive Pulmonary Disease (COPD), Infectious Diseases, Asthma, Others. By Geography: North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa. Among these regions, North America holds the largest share in the market. Market Size Data Forecast period: Historical and Future By region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa. By countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. Major market players such as Covidien, GE Healthcare, Philips Healthcare, ResMed, Siemens Healthcare, Merck & Co., Calando Pharmaceuticals, Quark Pharmaceuticals, Sirnaomics Inc, and Traversa Therapeutics. Trends, opportunities, strategies and so much more. Respiratory Monitoring Devices Global Market Report 2022 is one of The Business Research Company’s comprehensive reports that provides respiratory monitoring devices market outlook, in-depth respiratory monitoring devices market research. The market report analyzes respiratory monitoring devices global market size, respiratory monitoring devices global market segments, respiratory monitoring devices global market growth drivers, respiratory monitoring devices global market growth across geographies, and respiratory monitoring devices global market competitors’ revenues and market positioning. The report enables you to gain insights on opportunities and strategies, as well as identify countries and segments with the highest growth potential. View similar reports by The Business Research Company: Anesthesia And Respiratory Devices Global Market Report 2022

Sirnaomics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Sirnaomics Rank

Sirnaomics Frequently Asked Questions (FAQ)

  • When was Sirnaomics founded?

    Sirnaomics was founded in 2007.

  • Where is Sirnaomics's headquarters?

    Sirnaomics's headquarters is located at 401 Professional Drive, Gaithersburg.

  • What is Sirnaomics's latest funding round?

    Sirnaomics's latest funding round is IPO.

  • How much did Sirnaomics raise?

    Sirnaomics raised a total of $267.68M.

  • Who are the investors of Sirnaomics?

    Investors of Sirnaomics include Rotating Boulder Fund, Sangel Capital, Walvax Biotechnology, Longmen Capital, Riverhead Capital and 17 more.

  • Who are Sirnaomics's competitors?

    Competitors of Sirnaomics include Dicerna Pharmaceuticals, MOgene LC, Blue Heron Biotech, Bar Harbor BioTechnology, Molecular Partners and 13 more.

Compare Sirnaomics to Competitors

MOgene LC

MOgene is a biotechnology company, focused on understanding the mechanisms of cellular and organismal toxicity of chemical compounds and applying the knowledge to improve safety and efficacy of products across life science industries. MOgene uses a systems biology approach to understand gene function in the context of biological networks, to develop assays and biomarkers for molecular diagnostic solutions that would help address toxicity issues. MOgene is an Agilent-certified gene expression service provider and aims to provide microarray services including custom design of arrays, experiment design and detailed bioinformatics analysis.

Bar Harbor BioTechnology Logo
Bar Harbor BioTechnology

Bar Harbor Biotech is a life sciences company spun-out from The Jackson Laboratory to develop gene expression products and services. Bar Harbor Biotech's technology focuses on real-time quantitative polymerase chain reaction (PCR), an established technique for gene expression used in disease research, molecular diagnostics, drug discovery, and other fields of biology research.


Welgen, Inc. is a biotech company developing technologies and products for biomedical research. The company was founded in 2002 to develop vectors for gene delivery and silencing that facilitate research activities in both academia and industry. The company's products provide the medical research community and the pharmaceutical industry with rapid and cost-efficient approaches for gene function research and drug development.

Agrisoma BioSciences

Agrisoma Biosciences is an agricultural company that has commercialized carinata, a non-food oilseed crop designed for sustainable production of biofuels. Agrisoma sells carinata seed products under the Resonance brand name, and uses advanced crop improvement technologies to provide superior crop varieties to growers.

Nuclea Biotechnologies

Nuclea Biotechnologies is a healthcare company dedicated to the development and commercialization of clinical diagnostic assays identifying gene and protein expression profiles characteristic of an individual's tumor or disease. Nuclea is committed to advancing discovery and validation of clinical test platforms that are predictive of a cancer patient\'s responsiveness to oncology therapeutics and the likelihood of disease recurrence. The Company utilizes translational medicine-based technology to refine the understanding of the biological principles underpinning human disease, enabling the discovery of disease specific biomarkers. The tests developed identify a patient\'s predictive response to a particular therapy or assess the risk of the disease developing or recurring later in life. Test results deliver valuable genetic information on the specific disease guiding treatment decisions.

Oceanit Logo

Oceanit creates solutions through engineering consulting in civil, coastal, and environmental engineering; information systems consulting; management consulting, including Design Thinking and scientific research.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.